Back to Search Start Over

CD4+ Th1 to the rescue in HER-2+ breast cancer

Authors :
Lea Lowenfeld
Shuwen Xu
Brian J. Czerniecki
Source :
OncoImmunology, Vol 8, Iss 10 (2019)
Publication Year :
2019
Publisher :
Taylor & Francis Group, 2019.

Abstract

HER2 overexpression leads to downregulation of MHC class-I. CD4+ Th1 cytokines, IFNγ and TNFα, and monoclonal antibodies, trastuzumab and pertuzumab, restore MHC class-I expression, and enable CD8+ recognition and cytolysis. Restoration of the anti-HER2 CD4+ Th1 immune response in combination with HER2 targeted therapy appear to be critical to successful anti-HER2 CD8+ immunotherapy.

Subjects

Subjects :
her2
cd8+ t-cells
mhc class-i
cd4+ t-cells
ifnγ
tnfα
monoclonal antibodies
trastuzumab
pertuzumab
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Details

Language :
English
ISSN :
2162402X
Volume :
8
Issue :
10
Database :
Directory of Open Access Journals
Journal :
OncoImmunology
Publication Type :
Academic Journal
Accession number :
edsdoj.19da134f669846d39b7dde7321d68435
Document Type :
article
Full Text :
https://doi.org/10.1080/2162402X.2015.1078062
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details